Solara Active Pharma Sciences Limited (NSE:SOLARA) announced on 19 August 2026 that its Rights Issue Committee approved the conversion of 2,79,582 partly paid-up rights equity shares into fully paid-up equity shares of face value Rs. 10 each, following receipt of the applicable call monies from shareholders.
Key Highlights
- The Rights Issue Committee, via a Circular Resolution dated 19 August 2026, approved the conversion of 2,79,582 partly paid-up rights equity shares into fully paid-up equity shares bearing ISIN INE624Z01016.
- Of the converted shares, 2,23,051 held under ISIN IN9624Z01022 had Rs. 262.50 paid per share and received the Second and Final Call Money of Rs. 112.50 per share.
- The remaining 56,531 shares under ISIN IN9624Z01014 had Rs. 131.25 paid per share and received both the First Call Money and Second and Final Call Money totalling Rs. 243.75 per share.
- Following the conversion, the company's paid-up capital stands at Rs. 48,16,16,569, comprising 4,80,81,817 fully paid-up equity shares alongside residual partly paid-up shares.
About the Company
Solara Active Pharma Sciences Limited (NSE:SOLARA) is an active pharmaceutical ingredients (API) manufacturer headquartered in Chennai, Tamil Nadu, with its registered office in Navi Mumbai. The company produces APIs across therapeutic areas including pain management and anti-retrovirals, serving regulated markets in the United States, Europe, and other geographies. It operates manufacturing facilities in India and is listed on both BSE and NSE under scrip code 541540 and symbol SOLARA respectively.
Announcement in Detail
The Rights Issue Committee of Solara Active Pharma Sciences resolved, through a Circular Resolution passed on 19 August 2026, to convert 2,79,582 partly paid-up rights equity shares into fully paid-up equity shares of face value Rs. 10 each. This follows the company's Final Reminder Cum Forfeiture Notice issued on 3 July 2026 to holders who had not yet paid outstanding call monies.
The first tranche covers 2,23,051 shares under ISIN IN9624Z01022, where the Second and Final Call Money of Rs. 112.50 per share (Rs. 3 face value plus Rs. 109.50 premium) was received. The second tranche covers 56,531 shares under ISIN IN9624Z01014, where both the First Call Money and Second and Final Call Money aggregating Rs. 243.75 per share (Rs. 6.50 face value plus Rs. 237.25 premium) were collected. The company has stated it will pursue listing and trading approvals for the converted shares.
Impact on Investors
Investors will note that the conversion increases the pool of fully paid-up equity shares eligible for regular trading on the exchanges. The filing shows that after this conversion, 59,419 shares at Rs. 7 partly paid and 1,09,276 shares at Rs. 3.50 partly paid remain outstanding under separate ISINs, meaning the rights issue process is not yet fully concluded for all subscribers.
Shareholders holding the converted shares will observe that these shares will move to the fully paid-up ISIN INE624Z01016 upon receipt of listing and trading approvals, aligning their tradability with the main equity. The disclosed terms indicate no change to the face value of Rs. 10 per share, and the conversion does not alter the existing rights of fully paid-up shareholders in terms of voting or dividend entitlement per share.
Sector / Market Context
India's API sector has been a focus of domestic manufacturing policy, with the government's Production Linked Incentive scheme for pharmaceuticals targeting capacity expansion in bulk drugs. According to the Pharmaceuticals Export Promotion Council of India, the country is among the largest global API suppliers by volume. Rights issues have been a common capital-raising instrument among Indian pharma companies seeking to fund capacity upgrades or reduce debt, making the completion of call money collections a standard but operationally significant step in the post-issue lifecycle.